Travere Therapeutics, Inc.
TVTX
Clasificación en acciones
#3626
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies... Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Precio por acción
$49.66
Última sincronización: 2026-10-16
Capitalización bursátil
$4.68B
Cambio (1 día)
-5.93%
Cambio (1 año)
81.77%
País
US
Comercio Travere Therapeutics, Inc. (TVTX)
Categoría
Healthcare
Margen Operativo de Travere Therapeutics, Inc. (TVTX)
Margen Operativo al October 2026 TTM: -6.84%
Según los informes financieros más recientes y el precio de las acciones de Travere Therapeutics, Inc., el margen operativo actual (TTM) es -6.84%. Al final de 2023, el margen operativo era -259.40%.
Historial de Margen Operativo de Travere Therapeutics, Inc. desde 2009 hasta 2026
Margen Operativo al final de cada año
| Año | Margen Operativo | Cambiar |
|---|---|---|
| 2026 (TTM) | -6.84% | -95.03% |
| 2024 | -137.51% | -46.99% |
| 2023 | -259.40% | 118.63% |
| 2022 | -118.65% | 93.49% |
| 2021 | -61.32% | 61.33% |
| 2020 | -38.01% | -33.22% |
| 2019 | -56.92% | 16.81% |
| 2018 | -48.73% | 40.35% |
| 2017 | -34.72% | -20.33% |
| 2016 | -43.58% | -14.21% |
| 2015 | -50.80% | -82.05% |
| 2014 | -282.97% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
Margen Operativo de empresas similares o competidoras
| Empresa | Margen Operativo | Diferencia de Margen Operativo | País |
|---|---|---|---|
| 38.59% | -105.64% |
US
|
|
| -149.01% | -78.21% |
US
|
|
| 25.57% | -103.74% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -104.21% |
NL
|
¿Qué es el Margen Operativo de una empresa?
El Margen Operativo es un indicador clave para evaluar la rentabilidad de una empresa. Un margen operativo más alto suele ser mejor, ya que indica que una empresa puede vender sus productos o servicios por mucho más de lo que cuestan producirlos. Se calcula dividiendo las ganancias de la empresa entre sus ingresos.